Algorithm for the management of ERCP-related perforations - 31/05/16
Abstract |
Background and Aims |
Perforation is a rare but serious adverse event of ERCP. There is no consensus to guide the clinician on the management of ERCP-related perforations, with particular controversy surrounding the immediate surgical management of postprocedurally detected duodenal perforation because of overextension of a sphincterotomy. Our aim was to assess patient outcomes using a predetermined algorithm based on managing ERCP-related duodenal perforations according to the mechanism of injury.
Methods |
A retrospective single-center study of all consecutive patients with Stapfer type I and II perforations between 2000 and 2014 were included. Our institutional algorithm since 2000 dictated that Stapfer type I perforations (duodenal wall perforation, endoscope related) should be managed surgically unless prohibited by underlying comorbidities and Stapfer type II perforations (periampullary, sphincterotomy related) managed nonsurgically unless a deterioration in clinical status necessitated surgery.
Results |
Sixty-one patients (mean age, 51 years; 80% women) were analyzed with Stapfer type I perforations diagnosed in 7 (11%) and type II in 54 (89%). A postprocedural diagnosis of perforation was made in 55 patients (90%). Four patients (7%) had Stapfer type II perforations that failed medical management and required surgery. The mean length of stay (LOS) in the entire cohort was 9.6 days with a low mortality rate of 3%. Systemic inflammatory response syndrome was observed in 18 patients (33%) with Stapfer type II perforations and was not associated with the need for surgery. Concurrent post-ERCP pancreatitis was diagnosed in 26 patients (43%) and was associated with an increased LOS.
Conclusions |
Stapfer type II perforations have excellent outcomes when managed medically. We validate an algorithm for the management of ERCP-related perforations and propose that it should function as a guide.
Il testo completo di questo articolo è disponibile in PDF.Abbreviations : CCI, LOS, SIRS, PEP
Mappa
| DISCLOSURE: The following authors disclosed financial relationships relevant to this publication: M. A. Khashab: Consultant for Boston Scientific and Olympus America and research support recipient from Cook Medical; A. N. Kalloo: Founding member, equity holder, and consultant for Apollo Endosurgery; V. K. Singh: Consultant for Abbvie, D-Pharm, Boston Scientific, Interscope, Calcimedica, and Novo Nordisk and advisory board participant for Salix and Enteromedics. All other authors disclosed no financial relationships relevant to this publication. |
Vol 83 - N° 5
P. 934-943 - maggio 2016 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?
